Coimmunocapture and Electrochemical Quantitation of Total and Phosphorylated Amyloid-β40 Monomers.
Phosphorylated proteins play important roles in the pathogenesis of Alzheimer's disease (AD). The most abundant constituent in AD's brain deposit is the amyloid-β40 peptide (Aβ40). Based on it, the degree of phosphorylated Aβ40 in body fluids (e.g., cerebrospinal fluid, CSF), which is defined by the ratio of phosphorylated Aβ40 to total Aβ40 (pAβ40/tAβ40), is anticipated to be an index for early diagnosis of AD. The major challenge in pAβ40/tAβ40 detection is the large concentration difference between two Aβ40 forms in the real samples, which usually requires multichannel equipment and complicated detection process. In this paper, we revealed the unexpected close affinities of the anti-Aβ40 antibody to Aβ40 (40.2 nM-1) and to pAβ40 (42.3 nM-1). Based on it, a convenient coimmunocapture and electrochemical quantitation of tAβ40 and pAβ40 was achieved on an anti-Aβ40 antibody immobilized Au electrode (anti-Aβ40/Au). Once Aβ40 and pAβ40 were synchronously captured on the anti-Aβ40/Au electrode, the tAβ40 levels in CSF samples were quantified with electrochemical impedance spectroscopy. With the signal amplification from Cd2+/Ti4+-functionalized titanium phosphate nanospheres (Cd2+/Ti4+@TiP) which was selective conjugated to pAβ40, concentrations of low abundant pAβ40 as low as 1 fM were readily measured by square wave voltammetry. Our results reveal that despite the concentrations of tAβ40 and pAβ40 fluctuate in each individual case, the concentration ratios of pAβ40/tAβ40 in CSF samples from AD patients are significant larger than those from healthy donors. It demonstrates that the degree of phosphorylated Aβ40 is hopeful to be an effective index for evaluating the AD progress and improving the accuracy of clinic AD diagnosis.